Heidi Crayton, MD, and Maria Lopes, MD, discuss the most recent 2018 guidelines for multiple sclerosis treatment, emphasizing the need for updated guidelines, particularly in the payer space, to ...

A simple algorithm to aid in the selection of appropriate disease modifying therapies (DMTs) reduces racial disparities in patients with relapsing multiple sclerosis (MS), early new research showed.

A simple treatment algorithm may help reduce treatment disparities for Hispanic and Black people with multiple sclerosis (MS), according to a preliminary study released today, March 3, 2025, that will ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

LOS ANGELES — New guidelines on the use of disease-modifying therapies (DMTs) in patients with multiple sclerosis (MS) provide updated guidance on starting, switching, and stopping treatment and ...

Dr Haumschild leads a discussion surrounding patient and provider collaboration to avoid clinical inertia in MS treatment pathways. Ryan Haumschild, PharmD, MS, MBA: One of the things I see is, ...

Share on Pinterest A recent study reports that starting treatment at the first signs of MS symptoms could help slow disease progression. Jennifer Blount/Getty Images A recent study finds getting ...

A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis (MS) in Finland between 2013 and 2022. According to the study published in ...